Navigation Links
Allegheny General Hospital Study Demonstrates Safety and Potential Efficacy of Oral Allergy Treatment
Date:2/12/2010

Medication Delivered Under the Tongue May Be Alternative to Allergy Shots

PITTSBURGH, Feb. 12 /PRNewswire-USNewswire/ -- An oral allergy treatment administered in drops under the tongue is a safe and effective alternative to injections for adults who are allergic to ragweed pollen, according to a study published today in the Journal of Allergy and Clinical Immunology by allergic disease specialist at Allegheny General Hospital.  

Widely used in Europe, but not yet approved by the U.S. Food and Drug Administration, sublingual allergen immunotherapy (SLIT) can be a more convenient and tolerable treatment approach that leads to greater patient compliance, said David Skoner, MD, director of AGH's Division of Allergy, Asthma and Immunology and a co-lead investigator in the study.  

"The study's findings mark a step forward in gaining approval for sublingual administration of allergy medication," said Dr. Skoner, "We believe a large number of patients would greatly benefit from having access to this new oral treatment to ease their symptoms."

"The sublingual method so far has been safe, and the adherence rate should be better because no injections are involved and the medication is administered at home," said co-investigator Deborah Gentile, MD, Director of Research in AGH's Division of Allergy, Asthma and Immunology.

The AGH study, "Sublingual Immunotherapy in Patients with Allergic Rhinoconjunctivitis Caused by Ragweed Pollen," involved 115 patients in Pittsburgh, Madison, Wisc., Iowa City and Evansville, Ind. They were randomly assigned to a medium or high dose of standardized glycerinated short ragweed pollen extract or to a placebo.  Participants kept diaries to monitor their symptoms over the course of 17 weeks during the ragweed pollen season.

The frequency of daily symptoms, as well as the need for additional medication to treat symptoms, both dropped significantly for those taking the high-dose medication, versus those taking a placebo. The frequency of adverse events was similar between the placebo and treatment groups.

The researchers concluded that SLIT was safe and can reduce symptoms in ragweed-sensitive patients, though more trials are needed to definitively establish the method's efficacy.

Shortcomings of previous trials with the sublingual method included small patient populations, high withdrawals and short treatment duration. Questions remaining on SLIT include treatment schedules, optimal doses and cost-effectiveness.

Other researchers involved in the study were Robert Bush, MD of the University of Wisconsin School of Medicine and Public Health; Mary Beth Fasano, MD, University of Iowa Hospitals and Clinics; Anne McLaughlin, MD, of Wellborn Clinical Research Center in Evansville, Ind., and Robert E. Esch, PhD, of Greer Laboratories Inc., Lenoir, NC.

SOURCE Allegheny General Hospital


'/>"/>
SOURCE Allegheny General Hospital
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. State Health, Education Leaders Hail Avonworth Middle School in Allegheny County for Boosting Physical Activity Among Students
2. Allegheny Medical Achieves Remarkable Success with Their Fibromyalgia Flow Care Plan
3. Allegheny Medical Announces Launch of the New AlleghenyMedical.com
4. Allegheny County Health Department and School Districts Misinforming the Public
5. West Penn Allegheny Health System Files Lawsuit Charging UPMC, Highmark with Conspiracy, Antitrust
6. Pennsylvania State Department of Health and Allegheny County Health Department Confirm Four Cases of Measles in Southwest Region
7. Psychology of Face Transplants is Subject of New Book by Allegheny College Professor
8. Standard & Poors Removes West Penn Allegheny Health System Bonds From Credit Watch
9. Moodys Removes West Penn Allegheny Health System From Watchlist
10. Pennsylvania Commission for Women Delivers First Womens Wellness Guide Kiosk to Allegheny County Jail
11. West Penn Allegheny Health System Adjusts Balance Sheet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... , ... May 31, 2016 , ... WaterField Designs, an ... professionals, announces the waxed-canvas and leather Duo Dopp Kit , the ideal gift ... or ballistic nylon, the Duo is smartly designed for Dad’s grooming routine. ...
(Date:5/31/2016)... CA (PRWEB) , ... May 31, 2016 , ... Interest ... a primary screening tool and as an orthogonal tool for RNAi hit validation. A ... functional and specific guide RNAs—allows rapid generation of CRISPR RNA (crRNA) collections in arrayed ...
(Date:5/31/2016)... ... 2016 , ... MinerEye today announced that it has been ... by Gartner1 Inc. , Each year, Gartner identifies new Cool Vendors in key ... and their products and services. , According to Gartner, “Gartner's Cool Vendors in ...
(Date:5/31/2016)... ... May 31, 2016 , ... CURE Media Group ... cancer, has added Cancer and Careers to its Advocacy Spotlight ... on continuing successful careers while fighting cancer. , As partners, both organizations will ...
(Date:5/30/2016)... , ... May 30, 2016 , ... ... businesses, announced today the publication of an original infographic, " Health Benefits Reimbursement ... insurance professionals understand how Zane Benefits complies with various federal regulations and reforms. ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 26, 2016   Change Healthcare , ... network solutions and technology-enabled services designed to ... into a strategic channel partnership with SourceMed, ... solutions and revenue cycle management services that ... rehabilitation clinics to optimize revenue, operational efficiency ...
(Date:5/25/2016)... FDA 510(k) clearance covers Confocal Miniprobes ... and surgical applications Mauna Kea Technologies ... multidisciplinary confocal laser endomicroscopy (CLE) platform, today announced ... the 12 th 510(k) clearance from United ... FDA clearance covers Confocal Miniprobes indicated for use ...
(Date:5/25/2016)... , Deutschland und GERMANTOWN, Maryland ... Zusammenarbeit mit Therawis bedient dringenden ... Brustkrebs   QIAGEN N.V. (NASDAQ: ... heute bekannt, eine Lizenz- und Entwicklungsvereinbarung mit Therawis ... für die Onkologie eingegangen zu sein. Ein erstes ...
Breaking Medicine Technology: